Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CMC Biologics, a contract biopharmaceutical manufacturing and development firm, is on the verge of completing the ongoing expansion of its stainless steel biomanufacturing production facility PF2 in Bothell campus.
Subscribe to our email newsletter
With this expansion, the company anticipates to add a 3,000 liter bioreactor train to increase commercial manufacturing in its PF2 site.
The expansion, which is originally started in 2010 with the construction of a multipurpose single-use facility (PF1), expects to include the build-out of a facility to house two 5,000 liter commercial-ready manufacturing lines.
Additionally, the company has also rebranded its corporate image with a new logo and an additional tag line.
CMC Biologics global chief operations officer Gustavo Mahler said the expansion of PF2 will add significant production capacity to CMC Biologics’ existing facilities to accommodate growing demand for cGMP manufacture of biopharmaceuticals.